On Feb 19th 2020, two novel coronavirus detection products developed by Guangzhou Wondfo Biotech Co.,Ltd., had the honor to access to emergency approval channel issued by National Medical Products Administration under recommendation of Scientific research team of Joint Prevention and Control Mechanism of the State Council. This opening bidding has 300 applications. Only a total of 9 programs were selected this time, 2 of them are originated from Wondfo.
One of listed products developed by Wondfo is novel coronavirus (COVID-19) antigen rapid test kit. It is suitable for conducting a large scale on-site coronavirus screening.
Another product is novel coronavirus (COVID-19) antibody rapid test kit which is based on fluorescence microsphere/colloidal gold immunochromatography technology.
As a leading enterprise of POCT, Wondfo has been dedicating to make good use of our technological advantages to combat against novel coronavirus (COVID-19) epidemic. Clinical verifications and registration of novel coronavirus rapid test kits run smoothly so far, and we will keep attaching great importance to accelerate the process of fighting the epidemic.
From SARS to H1N1、H7N9 outbreak，from Flu to COVID-19 epidemic, Wondfo always fight against the disease in the frontline with the conviction that life is our top priority.